Author’s Reply

To the Editor,

We thank you for your comments on our study published in the September 2014 issue of The Anatolian Journal of Cardiology entitled ‘Assessment of serum hepcidin levels in patients with non-ST elevation myocardial infarction (NSTEMI).’ (1). They have raised some questions. Hepcidin is produced mainly in the liver and increases in response to inflammation, and its expression is regulated by anemia, hypoxia, and inflammation (2). In this single-center study, we evaluated whether the level of hepcidin increased in the acute phase in NSTEMI, known as acute inflammatory aggravation of a chronic atherosclerotic process.

There are conflicting results for hepcidin in coronary artery disease patients (3, 4). The first remark was about blood sampling time and symptom onset. We did not investigate hepcidin kinetics in this study; our aim was fundamentally to use hepcidin as a new cardiac marker instead of troponin. Another remark was about the time interval between the onset of the symptoms and blood sampling. According to our study design, we aimed to compare hepcidin levels with troponin levels in the diagnosis of NSTEMI. It is important that the hepcidin levels did not decrease; meanwhile, the levels of troponin were increased in NSTEMI patients in the acute phase. The observed differences in these parameters, performed simultaneously from the same patients, forced us to think that there was no need to take the time interval between the onset of symptoms and blood sampling. The other remark was about the study of Suzuki et al. (4). The patient population and the design of the two studies were different, as the authors (4) studied ST elevation myocardial infarction patients, but we did not. Also, the sample of their study was extremely low, and their aim was also different. As stated in the criticism, if we performed a correlation analysis between CRP and hepcidin levels, it should have corroborated our results, showing hepcidin as a surrogate marker of inflammation.

Burak Altun, Hakan Taşolar1, Mehzat Altun*
Departments of Cardiology, *Vocational Health College, Faculty of Medicine, Çanakkale Onsekiz Mart University; Çanakkale-Turkey
1Department of Cardiology, Adiyaman University Training and Research Hospital; Adiyaman-Turkey

References

great arteries in patients with transposed great arteries who had a sternotomy redone in the Fontan operation.

If it is complicated to close the pulmonary antegrade flow during the Fontan procedure due to transposition of the great arteries, transcatheter intervention can be performed safely and effectively after the surgery.

Alper Güzeltaş, İbrahim Cansaran Tanıdır, Murat Saygı
Department of Pediatric Cardiology, Mehmet Akif Ersoy Cardiovascular Research and Training Hospital; Istanbul-Turkey

References

Address for Correspondence: Dr. Alper Güzeltaş, Istanbul Mehmet Akif Ersoy Eğitim Araştırma Hastanesi İstasyon Mah. Turgut Özal Bulvarı No:11, Küçükçekmece, İstanbul-Türkiye
Phone: +90 212 692 20 00
Fax: +90 212 471 94 94
E-mail: alperturgutsalt@hotmail.com
Available Online Date: 21.01.2015
©Copyright 2015 by Turkish Society of Cardiology - Available online at www.anakarder.com
DOI:10.5152/akd.2015.6045

Author’s Reply

To the Editor,

We would like to thank the authors of the letter for their interest about our paper entitled "Transcatheter closure of antegrade pulmonary blood flow with Amplatzer muscular VSD occluder after Fontan operation. Anatolian J Cardiol 2014; 14: 565 (1). In 1971, Fontan and Baudet described a surgical procedure for repair of tricuspid atresia that built on experimental and clinical research from the 1940s. Today, the Fontan procedure is the most commonly performed staged palliative surgical procedure in patients with single ventricle physiology to ultimately create a circulatory system driven by a single ventricle without passing the right ventricle (2). It has been performed to treat several complex congenital heart diseases, including tricuspid atresia, hypoplastic left heart syndrome, pulmonary atresia with intact ventricular septum, and double-inlet ventricle.

At the time of the Fontan procedure, it is necessary to remove all origins of supplemental pulmonary blood flow to avoid volume loading of the heart. However, this can result in acute reduction in ventricular preload and diastolic dysfunction in the early postoperative period (3). In addition, some studies reported that non-pulsatile pulmonary blood flow decreased capillary flow and increased vascular resistance (2). On the other hand, there is a risk of persistent pleural effusions or progressive ventricular failure in patients having forward flow from the ventricle to the pulmonary arteries after Fontan procedure (3). As a result, it is controversial as to whether additional sources of systemic to pulmonary artery flow are beneficial or not.

Transcatheter closure of accessory antegrade pulmonary blood flow is an alternative to surgery, because it is less invasive, easy to perform, reliable, and more comfortable (4, 5). Numerous kinds of devices are now commercially available for the closure. Petko et al. (4) showed that the off-label use of Amplatzer Septal or Ductal Occluders or an Amplatzer Vascular Plug for the closure was effective for the reduction of ventricular volume load and resolution of the pleural effusions, which can occur as a complication after cavopulmonary shunt or Fontan procedure. Desai et al. (3) also reported that the use of a Raskind Umbrella Occluder or Amplatzer Septal or ductal occluder for the closure was a safe and effective technique after cavopulmonary shunt or Fontan procedure.

In my opinion, an issue that is worthy of discussion may be the thrombotic problems in the author’s case. Devices can be placed to the pulmonary artery band or pulmonary valve tissue or above the pulmonary valve (4). The place and approach for occlusion can be modified by patient anatomy and technical ease. By the way, if there is room between the pulmonary valve and device, the stasis of blood in the room can lead to formation of a thrombus. The thrombus is also possible to occur as a complication after cavopulmonary shunt or Fontan procedure.

If it is complicated to close the pulmonary antegrade flow during the Fontan procedure due to transposition of the great arteries, transcatheter intervention can be performed safely and effectively after the surgery.

Mustafa Gülgün1, Tevfik Karagöz2
1Department of Pediatric Cardiology, Gülhane Military Medical Academy; Ankara-Turkey
2Department of Pediatric Cardiology, Faculty of Medicine, Hacettepe University; Ankara-Turkey

References

Address for Correspondence: Dr. Mustafa Gülgün,
Gülhane Askeri Tip Akademisi, Pediyatrik Kardiyoloji Bölümü 06010 Etilik, Ankara-Türkiye
Phone: +90 312 304 43 93
Fax: +90 312 304 43 81
E-mail: mustafagulgun@yahoo.com, mgulgun@gata.edu.tr
Available Online Date: 21.01.2015

Basilic vein transposition should be the first option

To the Editor,

We have read with great interest the article, entitled ‘Long-term patency of autogenous saphenous veins vs. polytetrafluoroethylene